1. Home
  2. IGI vs ACET Comparison

IGI vs ACET Comparison

Compare IGI & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Investment Grade Defined Opportunity Trust Inc.

IGI

Western Asset Investment Grade Defined Opportunity Trust Inc.

HOLD

Current Price

$15.97

Market Cap

96.4M

Sector

Finance

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.71

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IGI
ACET
Founded
N/A
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.4M
77.3M
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
IGI
ACET
Price
$15.97
$7.71
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
26.3K
84.7K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.78
$0.46
52 Week High
$17.09
$9.05

Technical Indicators

Market Signals
Indicator
IGI
ACET
Relative Strength Index (RSI) 40.06 47.05
Support Level $15.78 $7.50
Resistance Level $16.57 $8.68
Average True Range (ATR) 0.15 0.53
MACD -0.00 -0.07
Stochastic Oscillator 16.97 24.22

Price Performance

Historical Comparison
IGI
ACET

About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.

Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: